Tango Therapeutics Inc Market Cap ($3.80 Billion)
Market Cap & Net Worth: Tango Therapeutics Inc (TNGX)
Tango Therapeutics Inc market cap. Tango Therapeutics Inc (NASDAQ:TNGX) has a market capitalization of $3.80 Billion ($3.80 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4144 globally and #1470 in its home market, demonstrating a -16.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tango Therapeutics Inc's stock price $22.53 by its total outstanding shares 168610367 (168.61 Million).
Tango Therapeutics Inc Market Cap History (2020–2026)
Tango Therapeutics Inc market cap history from 2020 to 2026. Data shows growth from $1.93 Billion to $3.80 Billion (13.68% CAGR). Check TNGX stock price and chart for real-time trading data and today's change.
Index Memberships
Tango Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.14% | #109 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #483 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.21% | #69 of 263 |
Weight: Tango Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tango Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tango Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Tango Therapeutics Inc (TNGX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
23.95x
Tango Therapeutics Inc's market cap is 23.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.93 Billion | $7.66 Million | -$51.97 Million | 251.95x | N/A |
| 2021 | $1.84 Billion | $37.04 Million | -$58.23 Million | 49.80x | N/A |
| 2022 | $1.22 Billion | $24.86 Million | -$108.18 Million | 49.17x | N/A |
| 2023 | $1.67 Billion | $36.53 Million | -$101.74 Million | 45.70x | N/A |
| 2024 | $521.01 Million | $42.07 Million | -$130.30 Million | 12.38x | N/A |
| 2025 | $1.49 Billion | $62.38 Million | -$101.59 Million | 23.95x | N/A |
Competitor Companies of TNGX by Market Capitalization
Companies near Tango Therapeutics Inc in the global market cap rankings as of October 31, 2026. See Tango Therapeutics Inc (TNGX) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Tango Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Tango Therapeutics Inc (2020–2026)
Market capitalization of Tango Therapeutics Inc from 2020 to today. Between 2020 and today, Tango Therapeutics Inc's market cap moved from $1.93 Billion to $ 3.80 Billion, with a yearly change of 13.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.80 Billion | +154.29% |
| 2025 | $1.49 Billion | +186.73% |
| 2024 | $521.01 Million | -68.79% |
| 2023 | $1.67 Billion | +36.55% |
| 2022 | $1.22 Billion | -33.73% |
| 2021 | $1.84 Billion | -4.37% |
| 2020 | $1.93 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Tango Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.80 Billion USD |
| MoneyControl | $3.80 Billion USD |
| MarketWatch | $3.80 Billion USD |
| marketcap.company | $3.80 Billion USD |
| Reuters | $3.80 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more